Brief: GeNeuro Announces First Patients Recruitment In Trial Assessing Temelimab Against Long-Covid
16/11/2022 06:38
Nov 16 (Reuters) - Geneuro SA GNRO.PA :
* GENEURO ANNOUNCES RECRUITMENT OF FIRST PATIENTS IN ALL
FIVE
SWISS CENTERS IN THE FIRST PERSONALIZED MEDICINE CLINICAL TRIAL
AGAINST LONG-COVID ASSESSING TEMELIMAB
* TOP-LINE RESULTS OF THE TRIAL ARE EXPECTED IN THE SECOND
HALF OF
2023
Source text for Eikon: ID:nBw4xTs36a
Further company coverage: GNRO.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Geneuro SA
See all newsBrief: Geneuro SA Postpones Publication Of Half-Yearly Financial Report
Brief: Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium
Brief: Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas
Brief: Geneuro Confirms Top-Line Results In Its Post-Covid Trial By End-June
Brief: Geneuro announces EUR 5 Mln private placement